Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice.

scientific article published in June 2008

Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1089/HUM.2008.012
P698PubMed publication ID18500943
P5875ResearchGate publication ID5349152

P50authorMichela A. DentiQ38320761
Tania IncittiQ39692804
Emanuele RizzutoQ43270254
Alberto AuricchioQ56950196
Carmine NicolettiQ57090924
Antonio MusaròQ71815476
P2093author name stringFernanda Gabriella De Angelis
Irene Bozzoni
Olga Sthandier
P433issue6
P304page(s)601-608
P577publication date2008-06-01
P1433published inHuman Gene TherapyQ15757580
P1476titleLong-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice
P478volume19

Reverse relations

cites work (P2860)
Q39932620Accurate quantification of dystrophin mRNA and exon skipping levels in duchenne muscular dystrophy.
Q37944530Cell-matrix interactions in muscle disease
Q37277411Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy
Q34994545Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.
Q33625875Delivery is key: lessons learnt from developing splice-switching antisense therapies
Q38089175Design and development of antisense drugs.
Q41671504Double-target Antisense U1snRNAs Correct Mis-splicing Due to c.639+861C>T and c.639+919G>A GLA Deep Intronic Mutations.
Q41136576Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts
Q39692533Exon skipping and duchenne muscular dystrophy therapy: selection of the most active U1 snRNA antisense able to induce dystrophin exon 51 skipping
Q42962196Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations
Q37519650Gene therapy for muscular dystrophy: current progress and future prospects.
Q33712930Gene-mediated restoration of normal myofiber elasticity in dystrophic muscles
Q35014916Interventions for muscular dystrophy: molecular medicines entering the clinic
Q35133936Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice
Q33573648Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers
Q35802092Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping
Q35612576Long-term systemic myostatin inhibition via liver-targeted gene transfer in golden retriever muscular dystrophy
Q38014478Making sense of therapeutics using antisense technology
Q37188213Modulation of caspase activity regulates skeletal muscle regeneration and function in response to vasopressin and tumor necrosis factor
Q33628125Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.
Q38168863New developments in the use of gene therapy to treat Duchenne muscular dystrophy
Q37814437New insights in gene-derived therapy: the example of Duchenne muscular dystrophy
Q37867701Opportunities and challenges for the development of antisense treatment in neuromuscular disorders
Q42587467Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy
Q37609948Progress in therapeutic antisense applications for neuromuscular disorders
Q92162442RNA Therapeutics: How Far Have We Gone?
Q38079633Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies
Q28291547Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice
Q27009581Splicing therapy for neuromuscular disease
Q36529176The lack of the Celf2a splicing factor converts a Duchenne genotype into a Becker phenotype
Q34473336The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy
Q38289261Viral Vector-Mediated Antisense Therapy for Genetic Diseases
Q24608004miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy
Q42126374miRNAs as serum biomarkers for Duchenne muscular dystrophy

Search more.